Results From TAVR Clinical Trial Show Positive Outcomes for Patients in First 30 Days | MedStar Health
![tavr-mhri](/-/media/project/mho/medstar/news-images/mhri/tavr-mhri.jpg?h=800&iar=0&w=1600&hash=13153875EF9FBD76A60BCEE6B741680D)
The researchers from MedStar Heart & Vascular Institute, led by Ron Waksman, MD, found, in their first-of-its-kind trial, that transcatheter aortic valve replacement in patients with low surgical risk showed no deaths or disabling strokes within 30 days of undergoing the procedure. This is a “strong signal” that it is safe for these patients as an alternative to the current standard of care. Read more.